PFS
KYMR icon

Prospera Financial Services’s Kymera Therapeutics KYMR Stock Holding History

Prospera Financial Services’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-136
Closed -$6K – 2160
2022
Q1 		$6K Buy
+136
New +$5.74K ﹤0.01% 2214

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Prospera Financial Services's KYMR Position: Q2 2022 in Review

Prospera Financial Services sold out of Kymera Therapeutics (KYMR) in Q2 2022, closing a stake of 136 shares — an estimated $6K sold.

Prospera Financial Services first reported a position in KYMR in Q1 2022 and held it in 1 quarter. The position peaked at $6K in Q1 2022. 100 funds tracked by Wall St. Rank hold KYMR as of Q2 2022.

  • Prospera Financial Services reported no remaining Kymera Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 136 Kymera Therapeutics shares in Q2 2022, an estimated $6K.
  • Prospera Financial Services first reported a position in Kymera Therapeutics in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Kymera Therapeutics position peaked at $6K in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.